Show Summary Details
Page of

Benign prostatic hyperplasia and prostate cancer 

Benign prostatic hyperplasia and prostate cancer
Benign prostatic hyperplasia and prostate cancer

Richard Savdie

, Edmund C. P. Chedgy

, and Chidi Molokwu

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 26 January 2022

The most common pathologic conditions of the prostate are benign prostatic hyperplasia (BPH) and prostate cancer. Both of these conditions have age as a risk factor. Therefore the importance of understanding their impact in the ageing male is clear. In particular, both of these conditions can have an effect on quality of life in the ageing male.

This chapter will aim to evaluate the background and diagnostic differences between the two conditions, with a focus on the benefits and pitfalls of prostate-specific antibody (PSA) testing. Furthermore, the effects of both these common conditions, including their impact on the male lower urinary tract, are explored. Subsequently, a focused outline of the treatment options for both BPH and prostate cancer will be presented. The discussion will focus on mechanisms of optimizing treatment options in an elderly population. Finally, the potential complications of different treatments for prostate cancer will be explored.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.